Based on PAS staining and calculated sclerosis scores, the development of glomerular sclerosis appeared to be milder in the febuxostat-treated gddY than in the untreated gddY mice, but this difference did not reach statistical significance ( p = 0.05) ( Figure 2 B).
← all excerpts
The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model.
1
0.0500
0.0500